Past studies [10,19,27] have implicated ATF5, CEBPB and CEBPD in the regulation of cancer cell responsiveness to the microtubule-targeting drug Taxol (paclitaxel), which is used to treat breast and other tumor types. The gene discussed is CEBPB; the disease is neoplasm.